Detection, inhibition and molecular analysis of multidrug resistant aerobic Gram-negative clinical isolates from a tertiary hospital in Nigeria

Simple item page
dc.contributor.authorAdeluola, A.O.
dc.contributor.authorOyedeji, K.S.
dc.contributor.authorMendie, U.E.
dc.contributor.authorJohnson, J.R.
dc.contributor.authorPorter, J.R.
dc.date.accessioned2020-01-07T08:21:52Z
dc.date.available2020-01-07T08:21:52Z
dc.date.issued2018-01
dc.descriptionStaff publicationsen_US
dc.description.abstractThe challenge of combating the ever emerging multi-drug resistant (MDR) clinical isolates in the face of a slow rate of discovery of new classes of antibiotics is a problem in antibiotic chemotherapy. This study was aimed at (i) linking phenotypic antibiotic drug-resistance characteristics detected in randomly-sampled clinical isolates with detectable genetic markers. (ii) screening a suspected efflux pump inhibitor (EPI) [1-(3-(trifluoromethyl)benzyl]-piperazine (TFMBP)], which could be helpful in combating this challenge. Fifty-one isolates; 28 Klebsiella pneumonia, 3 E. Coli, 1 Enterobacter cloacae, 1 E. aerogenes, 5 Proteus mirabilis, 4 Providencia rettgeri, 1 P. stuartii, 1 Serratia liquefaciens, 6 S. odorifera, and 1 Acinetobacter baumannii obtained from infections of urinary tract, upper respiratory tract, gastrointestinal tract, ear swab, eye swab, and blood culture were screened for (i) antibiotic-susceptibility over a range of 11 classes of antibiotics, (ii) β-lactamase production, (iii) ESBL production and (iv) Efflux pump activity (EPA) in the presence and absence of 1-[3-(trifluoromethyl) benzyl]-piperazine (TFMBP). Molecular analysis was done using DNA extraction by boiling and the randomly-amplified polymorphic DNA (RAPD) polymerase chain reaction (PCR) procedure with 2% agarose gel electrophoresis stained with ethidium bromide at 10 µg/ml and visualized by UV trans-illumination. AmpC β-lactamase (4%) and K1 β-lactamase (5.8%) were detected with no carbapenemase producers. AcrA and AcrB marker genes were detected in 12% of the isolates while blaCTX-M (8%) and blaTEM (4%) were also detected. Antibiotic resistance due to EPA can be combated with a suitable EPI as demonstrated by TFMBP when combined with specific antibiotics.en_US
dc.identifier.citationAdeluola, A. O., Oyedeji, K. S., Mendie, U. E., Johnson, J. R., & Porter, J. R. (2018). Detection, inhibition and molecular analysis of multidrug resistant aerobic Gram-negative clinical isolates from a tertiary hospital in Nigeria. African Journal of Biomedical Research, 21(1), 15-21.en_US
dc.identifier.urihttps://ir.unilag.edu.ng/handle/123456789/7296
dc.language.isoenen_US
dc.publisherBioline International, African Journals online (AJOL)en_US
dc.relation.ispartofseriesAfrican Journal of Biomedical Research;Vol.21(1)
dc.subjectTFMBPen_US
dc.subjectEfflux pump activityen_US
dc.subjectESBLen_US
dc.subjectMDRen_US
dc.subjectCarbapenemaseen_US
dc.subjectResearch Subject Categories::PHARMACY::Pharmaceuticsen_US
dc.titleDetection, inhibition and molecular analysis of multidrug resistant aerobic Gram-negative clinical isolates from a tertiary hospital in Nigeriaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Detection and molecular analysis of MDR Gram-negatives.pdf
Size:
542.75 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pharmaceutics and Pharmaceutical Technology- Scholarly Publications